Approval · Notice of Compliance 5092 · 1995

3TC: Notice of Compliance 5092

Issued December 8, 1995

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 5092
Date: December 8, 1995
Company: Glaxo Wellcome Biochem Inc.
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Priority-NAS
Therapeutic class: Antiretroviral agent

Products in this notice

Brand	DIN	Status today
3TC	02192683	Marketed
3TC	02192691	Marketed

Medicinal ingredients

LAMIVUDINE 150 MG per TAB
LAMIVUDINE 10 MG per ML